ATAI

Atai stock hits 52-week high of $7.26

AtaiBeckley Inc. Stock 12‑Month Price Target Cut to $8.83, Implies 22% Upside

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

H.C. Wainwright reiterates Buy on Atai stock, $25 target

Atai stock hits 52-week high at 7.22 USD

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3

ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders

Jefferies downgrades Atai stock rating to hold on Lilly buyout

Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout

AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI